Spexis AG (XSWX:SPEX) Retained Earnings : CHF-53.20 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Spexis AG's retained earnings for the quarter that ended in Dec. 2023 was CHF-53.20 Mil.

Spexis AG's quarterly retained earnings declined from Dec. 2022 (CHF-33.77 Mil) to Jun. 2023 (CHF-37.58 Mil) and declined from Jun. 2023 (CHF-37.58 Mil) to Dec. 2023 (CHF-53.20 Mil).

Spexis AG's annual retained earnings declined from Dec. 2021 (CHF-21.65 Mil) to Dec. 2022 (CHF-33.77 Mil) and declined from Dec. 2022 (CHF-33.77 Mil) to Dec. 2023 (CHF-53.20 Mil).

Spexis AG Retained Earnings Historical Data

The historical data trend for Spexis AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Retained Earnings Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-329.93

-34.83

-21.65

-33.77

-53.20

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Retained Earnings	Get a 7-Day Free Trial													-21.65	-26.67	-33.77	-37.58	-53.20

Spexis AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Spexis AG (XSWX:SPEX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines